Pfizer Articles
UNITAID HIV patent pool could save over $1 billion a year, put pressure on AIDS drugmakers
17 December 2009
Takeda gets rights to Seattle’s brentuximab and picks Pfizer for Actos in China; and Amgen licenses diabetes drug
15 December 2009
Pfizer fights back on HRT and cancer links highlighted by NYT
14 December 2009
Pfizer’s Aromasin little different to tamoxifen in disease progression for breast cancer patients
14 December 2009
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
Bristol-Myers Squibb and Pfizer to file apixaban In Europe; J&J unit submits palmitate for schizophrenia
7 December 2009
Watson buy of Arrow requires product divestments, says USA’s FTC
4 December 2009
Pfizer to pay Protalix up to $115 million in Gaucher's disease treatment deal; Genzyme’s Cerezyme supply
2 December 2009
Pfizer extends R&D operations in China
26 November 2009
Cancer pain drug market, fueled by opioids, will increase from $2.3 billion in 2008 to $3.7 billion in 2018
25 November 2009
Pfizer to be biggest beneficiary of China pharma market, say Goldman Sachs analysts; firm also set for Japanese generics market
24 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
Medicines top counterfeit concern list in Europe
23 November 2009
US FDA advisory panel backs Pfizer’s Prevnar 13
20 November 2009
US FDA warns against use of PPI Prilosec with Plavix
18 November 2009
Ph III results support Boehringer Ingelheim’s flibanserin as a potential female “Viagra”
17 November 2009
Corporate R&D investment in 2008: a global increase with EU companies leading USA and Japan; Pharma/biotech top sectors
16 November 2009
Former S-P chief Fred Hassan joins Bausch & Lomb board of directors
13 November 2009
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
13 November 2009
Pfizer disputes NEJM findings of skewing data on Neurontin
12 November 2009
Pfizer to close six global R&D sites as part of post-Wyeth acquisition cost-cutting
10 November 2009
US Justice Department probing Abbott Lab’s Depakote marketing
9 November 2009
More smokers quit habit with Pfizer’s Champix than with placebo
6 November 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Merck & Co - now world’s No 2 drugmaker - upbeat about new operation post Schering-Plough merger; but what about J&J?
5 November 2009
French crackdown on parallel drugs trade
4 November 2009
Johnson & Johnson to shed 6%-7% of jobs; confirms 2009 guidance
4 November 2009
Americans with heartburn paying too much for Nexium's 'Purple Pill,' claims Consumer Reports
30 October 2009
Pipeline launches in the RA market will be major contributor to market growth to $11.5 billion In 2018
28 October 2009
Batch of approvals and positive opinions from EU’s CHMP
26 October 2009
Animal research deserves defending
22 October 2009
Pfizer 2009 3rd-qtr earnings beats forecasts, but sales weaken
21 October 2009
US Court imposes record fine and forfeiture of $1.3 billion for Pfizer unit’s fraudulent marketing of Bextra
19 October 2009
Novartis to pay up to $485 million for Paratek’s IV antibiotic
12 October 2009
FDA panel OKs Pfizer’s Selzentry for broader us in HIV naive patients, but drug criticized for its cost
12 October 2009
$4 million milestone for Ablynx in Nanobody deal with Wyeth
1 October 2009
EU Commissioner Kroes still gunning for Pharma
30 September 2009
“No Frills Drugs” push Pharma to look for a cure
30 September 2009
BIO-Europe 2009: an opportunity to hunt for deals
25 September 2009
NICE backs use of sunitinib for the treatment of GISTs, but Pfizer to pay for first treatment cycle
23 September 2009
Senior management change at France’s Ipsen as Claude Bertrand joins
22 September 2009
VEM agrees to sell Ratiopharm; large number of interested parties
19 September 2009
Karo Bio buys rights to Pfizer thyroid hormone receptor platform
19 September 2009
“Novartis aims big in COPD market,” say Zacks analysts
17 September 2009
Changes predicted in renal cell carcinoma market leaders
15 September 2009
Public Citizen’s HRG slams Pfizer’s $2.3 billion settlement as not enough to deter bad behaviour by Pharma
9 September 2009
The pros and cons of authorized generics
4 September 2009
J&J decision to halt risperidone inj a setback for Alkermes’ pipeline, say analysts
1 September 2009
Pfizer and Private Access to develop on-line community to accelerate clinical research
20 August 2009
Indian patent law changes will benefit Pharma multinationals
19 August 2009
New top team at Takeda UK
17 August 2009
Adolor cuts back to focus on Entereg
5 June 2009
FDA eyes orlistat for potential liver problems, Chantix under scrutiny for skin reaction
5 June 2009
Japan pharma is not keen on transparency
4 June 2009
Preglem names Suhail Nurbhai CMO
4 June 2009
Pfizer halts Sutent Ph III breast cancer study
3 June 2009
Wyeth donates $100K to ASCO Cancer Foundation
1 June 2009
Gov't of Venezuela may buy Pfizer facility
1 June 2009
Wyeth presents strong combo drug data at ASCO
29 May 2009
Pfizer to raise $10.6B to finance Wyeth buy
28 May 2009
Retail drug sales in year to March 2009
22 May 2009
Pfizer
21 May 2009
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
